EyePoint Outperforms

Over the past year, EyePoint’s share price has outperformed the market by nearly 25%, delivering returns twice that of broader indices. All twelve analysts covering EYPT continue to recommend a Buy, reflecting confidence in the company’s prospects. The pipeline is built on proprietary bio‑erodible Durasert E technology, aimed at treating serious retinal diseases.